P1495: ETAVOPIVAT TREATMENT FOR UP TO 12 WEEKS IN PATIENTS WITH SICKLE CELL DISEASE IS WELL TOLERATED AND IMPROVES RED BLOOD CELL HEALTH

Detalles Bibliográficos
Autores principales: Saraf, S., Brown, R. C., Hagar, R. W., Idowu, M., Osunkwo, I., Kalfa, T. A., Kuypers, F. A., Geib, J., Schroeder, P., Wu, E., Kelly, P., Telen, M. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429144/
http://dx.doi.org/10.1097/01.HS9.0000848836.01685.87

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429144/
http://dx.doi.org/10.1097/01.HS9.0000848836.01685.87

Ejemplares similares